Exclusive

headquarters of Verily Life Sciences

Exclusive

Verily tangos at JPM with a health tech partner — and steps on a few toes

By Erin Brodwin

SHATTERED DIGIPILL

Exclusive

A forerunner in ‘smart pills’ adopts a new tack as key pharma partnership unravels

By Rebecca Robbins

OC Phases

Exclusive

The history of OxyContin, told through unsealed Purdue documents

By Shraddha Chakradhar and Casey Ross

Purdue docs

Exclusive

Purdue’s Richard Sackler proposed plan to play down OxyContin risks, and wanted drug maker feared ‘like a tiger,’ files show

George Church

Exclusive

Citing ‘nerd tunnel vision,’ biologist George Church apologizes for contacts with Jeffrey Epstein

By Sharon Begley

U.S. Capitol

Exclusive

PhRMA’s top lobbyist will leave at the end of August

By Nicholas Florko

Dr. Feng Zhang Broad Inst

Exclusive

The latest CRISPR patent fight is on. So is the mudslinging

By Sharon Begley

MilliporeSigma sign

Exclusive

Fight for coveted CRISPR patents gets knottier, as MilliporeSigma makes new claims

By Sharon Begley

Sean Parker reflection

Heavyweights

Billionaire Sean Parker is nerding out on cancer research. Science has never seen anyone quite like him

By Rebecca Robbins

Jennifer Doudna - Genome Editing Conference

Exclusive

GSK partners with CRISPR pioneer Doudna to search for new drugs

By Matthew Herper

Al Sandrock Biogen

Exclusive

One of the world’s best drug hunters went after Alzheimer’s. Here’s how he lost

By Matthew Herper

Ubiome Kit

Business

Troubled microbiome startup uBiome to lay off some employees, refund payments from federal insurers

By Rebecca Robbins

Spina Bifida

Exclusive

‘She’s wiggling her toes’: New fetal surgery for spina bifida may be safer for both baby and mom

By Usha Lee McFarling

Exclusive

Novartis may be close to settling a kickback case on the eve of a trial

By Ed Silverman

Vacuum tubes for blood analysis

Exclusive

New documents reveal Third Rock Ventures is set to launch a cancer diagnostics company

By Kate Sheridan

Exclusive

IBM halting sales of Watson AI tool for drug discovery amid sluggish growth

Great Hall of the People in Beijing

Exclusive

China creating national medical ethics committee to oversee high-risk clinical trials

By Jane Qiu

He Jiankui television screen cap

Exclusive

Chinese government funding may have been used for ‘CRISPR babies’ project, documents suggest

By Jane Qiu

Michael Deem photo illustration

Exclusive

American scientist played more active role in ‘CRISPR babies’ project than previously known

By Jane Qiu

Mitt Romney

Exclusive

Romney to speak before closed-door meeting of drug industry CEOs

By Nicholas Florko

Exclusive

In a sign of its concerns about Atul Gawande’s new venture, Optum sues over trade secrets

By Kate Sheridan and Casey Ross

Ginni Rometty CES

Exclusive

IBM isn’t retreating from using Watson in health care, CEO Rometty says

Exclusive

IBM Watson’s bet on China, a lucrative market for health business, starts to look shaky

By Casey Ross and Ike Swetlitz

NIH headquarters

Exclusive

Freeze on fetal tissue procurement may impede work at NIH cancer lab, agency says

By Ike Swetlitz

Cambridgeport

Exclusive

New documents shed light on secretive ElevateBio, next step for former Alexion execs

By Kate Sheridan

He Jiankui

Exclusive

Ethical issues plagued newly surfaced paper by ‘CRISPR babies’ scientist

By Sharon Begley

China Gene Edited Babies

Exclusive

‘CRISPR babies’ lab asked U.S. scientist for help to disable cholesterol gene in human embryos

By Sharon Begley

Genetic Frontiers Gene Edited Babies

Exclusive

UC Berkeley researcher, told of CRISPR’d baby study a year ago, warned scientist not to do it

By Rebecca Robbins

An embryo receives a small dose of Cas9 protein

Exclusive

He took a crash course in bioethics. Then he created CRISPR babies

By Sharon Begley